期刊的影响因子--文章列表

期刊文章列表
Siew-Fei Ngu，Hextan Y.S.Ngan，Karen K.L.Chan（Department of Obstetrics and Gynaecology）.A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy：a case report[J].癌症耐药(英文),2022,第3期 Amani Yehya，Fatima Ghamlouche，Amin Zahwe，Yousef Zeid，Kevork Wakimian，Deborah Mukherji，Wassim Abou-Kheir（Department of Anatomy；Division of Hematology/Oncology）.Drug resistance in metastatic castration-resistant prostate cancer：an update on the status quo[J].癌症耐药(英文),2022,第3期 Sasha C.Main，David W.Cescon，Scott V.Bratman（Princess Margaret Cancer Centre；Department of Medical Biophysics；Division of Medical Oncology and Hematology；Department of Radiation Oncology）.Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancer[J].癌症耐药(英文),2022,第3期 Gregory Bick，Jasmine Zhang，Elyse E.Lower，Xiaoting Zhang（Department of Cancer Biology；Department of Internal Medicine；University of Cincinnati Cancer Center）.Transcriptional coactivator MED1 in the interface of anti-estrogen and anti-HER2 therapeutic resistance[J].癌症耐药(英文),2022,第2期 Yuting Lu，Yongzhao Shao（Departments of Population Health and Environmental Medicine）.Multicellular biomarkers of drug resistance as promis-ing targets for glioma precision medicine and predic-tors of patient survival[J].癌症耐药(英文),2022,第2期 Tengda Zhao，Xueping Wang，Liwu Fu，Ke Yang（Department of Oral and Maxillofacial Surgery；Sun Yat-sen University Cancer center）.Fusobacterium nucleatum：a new player in regulation of cancer development and therapeutic response[J].癌症耐药(英文),2022,第2期 Jing Wu，Meng-Xuan Zhu，Ke-Sang Li，Ling Peng，Peng-Fei Zhang（Department of Medical Oncology；Cancer Center；Department of Hematology and Oncology；Department of Pulmonary and Critical Care Medicine）.Circular RNA drives resistance to anti-PD-1 immunotherapy by regulating the miR-30a-5p/SOX4 axis in non-small cell lung cancer[J].癌症耐药(英文),2022,第2期 Ahmed M.Elshazly，David A.Gewirtz（Department of Pharmacology and Toxicology；Department of Pharmacology and Toxicology）.An overview of resistance to Human epidermal growth factor receptor 2(Her2)targeted therapies in breast cancer[J].癌症耐药(英文),2022,第2期 Ravi Velaga，Sunao Tanaka，Masakazu Toi（Breast Surgery）.Molecular vulnerabilities and therapeutic resistance in hormone receptor positive and HER2 dependent breast cancer tumours[J].癌症耐药(英文),2022,第2期 Tomas Koltai（Former Medical Director of the Hospital del Centro Gallego de Buenos Aires）.The complex relationship between multiple drug resistance and the tumor pH gradient：a review[J].癌症耐药(英文),2022,第2期 Peter G.Rose（Section of Gynecologic Oncology）.Ovarian cancer recurrence：is the definition of platinum sensitivity modified by PARPi,bevacizumab or other intervening treatments?：a clinical perspective[J].癌症耐药(英文),2022,第2期 Michael J.Flynn，Jonathan A.Ledermann（Department of Oncology；UCL Cancer Institute）.Ovarian cancer recurrence：is the definition of platinum resistance modified by PARPi and other intervening treatments?The evolving landscape in the management of platinum-resistant ovarian cancer[J].癌症耐药(英文),2022,第2期 Deanna Tiek，Shi-Yuan Cheng（The Ken&Ruth Davee Department of Neurology）.DNA damage and metabolic mechanisms of cancer drug resistance[J].癌症耐药(英文),2022,第2期 Tanja Pejovic，Katherine Fitch，Gordon Mills（Knight Cancer Institute；Department of Obstetrics&Gynecology）.Ovarian cancer recurrence：“is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”[J].癌症耐药(英文),2022,第2期 Prem Prakash Kushwaha，Shiv Verma，Shashank Kumar，Sanjay Gupta（Department of Urology；The Urology Institute；Molecular Signaling and Drug Discovery Laboratory；Department of Pathology；Department of Pharmacology；Department of Nutrition；Divison of General Medical Sciences）.Role of prostate cancer stem-like cells in the development of antiandrogen resistance[J].癌症耐药(英文),2022,第2期 Mylena Ortiz，Emma Wabel，Kerry Mitchell，Sachi Horibata（Precision Health Program；Department of Pharmacology and Toxicology）.Mechanisms of chemotherapy resistance in ovarian cancer[J].癌症耐药(英文),2022,第2期 Naushair Hussain，Deea Das，Atreyi Pramanik，Manoj K Pandey，Vivek Joshi，Kartick C.Pramanik（Department of Biomedical Sciences；Department of Education；Department of Biomedical Sciences；Department of Biochemistry and Molecular Biology）.Targeting the complement system in pancreatic cancer drug resistance：a novel therapeutic approach[J].癌症耐药(英文),2022,第2期 Vanessa Eulo，Brian A.Van Tine（Division of Medical Oncology；Division of Medical Oncology；Division of Pediatric Hematology/Oncology；Siteman Cancer Center）.Immune checkpoint inhibitor resistance in soft tissue sarcoma[J].癌症耐药(英文),2022,第2期 VicençRuiz de Porras（Catalan Institute of Oncology；Germans Trias i Pujol Research Institute（IGTP））.Natural bioactive compounds：a potential therapeutic strategy to sensitize bladder cancer to cisplatin treatment?[J].癌症耐药(英文),2022,第2期 Quinty Hansen，Costa Bachas，Linda Smit，Jacqueline Cloos（Department of Hematology）.Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradication[J].癌症耐药(英文),2022,第2期 Pascale Palassin，Marion Lapierre，Sandrine Bonnet，Marie-Jeanne Pillaire，Balázs Győrffy，Catherine Teyssier，Stéphan Jalaguier，Jean-Sébastien Hoffmann，Vincent Cavaillès，Audrey Castet-Nicolas（IRCM；Institut de Pharmacologie et de Biologie Structurale；Department of Bioinformatics；Laboratoire de pathologie；Département de Pharmacie Clinique；Unitéde Formation et de Recherche des Sciences Pharmaceutiques et Biologiques）.RIP140 regulates POLK gene expression and the response to alkylating drugs in colon cancer cells[J].癌症耐药(英文),2022,第2期 Faustine Ong，Kunhwa Kim，Marina Y.Konopleva（Department of Leukemia）.Venetoclax resistance：mechanistic insights and future strategies[J].癌症耐药(英文),2022,第2期 Fatih M.Uckun（Departmens of Oncology and Developmental Therapeutics；Departmens of Translational Oncology）.Cancer drug resistance in multiple myeloma[J].癌症耐药(英文),2022,第2期 Xiaojin Guo，He Du，Jiayu Li，Menghang Yang，Anweng Xiong，Haiping Zhang，Fengying Wu（Department of Immuno-oncology；Department of Medical Oncology）.Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer：a retrospective study[J].癌症耐药(英文),2022,第1期 Lara Massai，Damiano Cirri，Tiziano Marzo，Luigi Messori（Department of Chemistry；Department of Chemistry and Industrial Chemistry；Department of Pharmacy；CISUP-Centre for Instrumentation Sharing（Centro per l’Integrazione della Strumentazione Scientifica）；University Consortium for Research in the Chemistry of Metal ions in Biological Systems（CIRCMSB））.Auranofin and its analogs as prospective agents for the treatment of colorectal cancer[J].癌症耐药(英文),2022,第1期 Casey D.Stefanski，Jenifer R.Prosperi（Department of Biological Sciences；Department of Biochemistry and Molecular Biology）.Combating CHK1 resistance in triple negative breast cancer：EGFR inhibition as potential combinational therapy[J].癌症耐药(英文),2022,第1期 Md Imtiaz Khalil，Arrigo De Benedetti（Department of Biochemistry and Molecular Biology）.Tousled-like kinase 1：a novel factor with multifaceted role in mCRPC progression and development of therapy resistance[J].癌症耐药(英文),2022,第1期 Yunchang Li，Lanlin Hu，Xinhao Peng，Huasheng Xu，Bo Tang，Chuan Xu（Integrative Cancer Center and Cancer Clinical Research Center；Collaborative Innovation Centre of Regenerative Medicine and Medical BioResource Development and Application）.Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer[J].癌症耐药(英文),2022,第1期 Xin Yu，Chaonan Han，Chunxia Su（Department of Oncology）.Immunotherapy resistance of lung cancer[J].癌症耐药(英文),2022,第1期 Samson Ghilu，Christopher L.Morton，Angelina V.Vaseva，Siyuan Zheng，Raushan T.Kurmasheva，Peter J.Houghton（Department of Molecular Medicine；Department of Surgery；Department of Epidemiology and Biostatistics）.Approaches to identifying drug resistance mechanisms to clinically relevant treatments in childhood rhabdomyosarcoma[J].癌症耐药(英文),2022,第1期首页上一页 1 2 3 下一页尾页共有3页，转到页

期刊文章列表